Market & Industry Briefs
Executive Summary
Brief summaries of recent medtech market and industry developments. This month we cover new clinical data on TAVI, declining CABG rates in US hospitals, and results from the CATT study comparing Lucentis and Avastin.
You may also be interested in...
Retinal Disease: Much Progress, Some Pain
On many fronts, 2011 was an event-filled year for the retinal disease market, beginning with the publication of the CATT trial comparing off-label intravitreal Avastin versus Lucentis for the treatment of AMD, and ending with several important milestones for device manufacturers operating in this space. But while the retinal device field is making progress in many areas, companies continue to struggle to meet shifting FDA approval requirements.
Start-Up News
Noteworthy news from medtech start-ups. This month's feature, "TAVI Halo Shines on Embolic Protection Devices," first appeared in the May 2011 issue of Start-Up.
Start-Up News
Noteworthy news from medtech start-ups. This month's feature, "TAVI Halo Shines on Embolic Protection Devices," first appeared in the May 2011 issue of Start-Up.